| Literature DB >> 35558882 |
Caroline Billings1, David E Anderson1.
Abstract
Osteomyelitis is an inflammatory bone disease typically caused by infectious microorganisms, often bacteria, which causes progressive bone destruction and loss. The most common bacteria associated with chronic osteomyelitis is Staphylococcus aureus. The incidence of osteomyelitis in the United States is estimated to be upwards of 50,000 cases annually and places a significant burden upon the healthcare system. There are three general categories of osteomyelitis: hematogenous; secondary to spread from a contiguous focus of infection, often from trauma or implanted medical devices and materials; and secondary to vascular disease, often a result of diabetic foot ulcers. Independent of the route of infection, osteomyelitis is often challenging to diagnose and treat, and the effect on the patient's quality of life is significant. Therapy for osteomyelitis varies based on category and clinical variables in each case. Therapeutic strategies are typically reliant upon protracted antimicrobial therapy and surgical interventions. Therapy is most successful when intensive and initiated early, although infection may recur months to years later. Also, treatment is accompanied by risks such as systemic toxicity, selection for antimicrobial drug resistance from prolonged antimicrobial use, and loss of form or function of the affected area due to radical surgical debridement or implant removal. The challenges of diagnosis and successful treatment, as well as the negative impacts on patient's quality of life, exemplify the need for improved strategies to combat bacterial osteomyelitis. There are many in vitro and in vivo investigations aimed toward better understanding of the pathophysiology of bacterial osteomyelitis, as well as improved diagnostic and therapeutic strategies. Here, we review the role of animal models utilized for the study of bacterial osteomyelitis and their critically important role in understanding and improving the management of bacterial osteomyelitis.Entities:
Keywords: Staphylococcus aureus; animal model; bone; in vivo; osteomyelitis
Year: 2022 PMID: 35558882 PMCID: PMC9087578 DOI: 10.3389/fvets.2022.879630
Source DB: PubMed Journal: Front Vet Sci ISSN: 2297-1769
Rat models of osteomyelitis.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
| *Rissing et al. ( | Model of experimental chronic osteomyelitis in rats | Albino Sprague-Dawley | 300–400 g | 35 and 70 days | Injection into intramedullary canal | Defect to tibial metaphysis, with medullary exposure, either | Histology, pathology, microbiology, radiographs, blood analyses | |
| Spagnolo et al. 1993 ( | Chronic | Male, Wistar | 250–350 g | 30, 60, 90 and 180 days | Injection into defect | Defects to tibial metaphyses bilaterally. Fibrin glue placed in defect. Sealed with bone wax | Radiographs, microbiology, histology, pathology | |
| *Hienz et al. ( | Development and characterization of a new model of hematogenous osteomyelitis in the rat | Female, Wistar | 200 g | 14 days | Intravenous injection | Drill defects to mandibular ramus and tibial metaphysis. Application of sclerosing agent. | Radiographs, microbiology, histology | |
| Lucke et al. ( | A new model of implant-related osteomyelitis in rats | Female, Sprague-Dawley | 5 months | 28 days | Injection into intramedullary canal | Burr defect into tibial metaphysis, placement of K-wire | Radiographs, blood and serum analyses, microbiology, histology | |
| *Fukushima et al. ( | Establishment of rat model of acute | Male, Wistar | 200–270 g | 7 days | Injection into intramedullary canal | Drill defect into tibial metaphysis, sealed with bone wax | Microbiology, pathology, histology | |
| Makinen et al. ( | Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to | Male, Sprague-Dawley | 380 g | 2 weeks | Injection into intramedullary canal | Drill defect into tibial metaphysis, application of sclerosing agent, sealed with bone wax | PET, pQCT, microbiology, histology, radiology | |
| Bisland et al. ( | Pre-clinical | Female, Sprague-Dawley | 250–300 g | At least 14 days | Bilateral defects to tibial metaphyses with medullary cavity exposure. K-wire inserted into medullary cavity. Sclerosing agent applied shortly after. Sealed with bone wax | Fluoroscopy, BLI | ||
| Aktekin et al. ( | A different perspective for radiological evaluation of experimental osteomyelitis | Female, Wistar albino | 6 months, 250 g | 3 and 6 weeks | Injection into intramedullary canal | Tibial intramedullary aperture by 19G needle and application of sclerosing agent. Sealed with bone wax | Radiographs, CT, DEXA scans | |
| Ofluoglu et al. ( | Implant-related infection model in rat spine | Male, Sprague-Dawley | 6 months, 300–350 g | 15 days | Injection into surgical site | Reaming of junction between vertebral lamina and facet joint, placement of titanium microscrew. | Microbiology, histology | |
| Robinson et al. ( | Development of a Fracture osteomyelitis model in the rat femur | Male, Sprague-Dawley | 250–300 g | 3 weeks | Injection into intramedullary canal | Defect to distal femur with medullary exposure. Stainless steel pin insertion. Sealed with bone wax | Radiographs, microbiology, histology | |
| Vergidis et al. ( | Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant | Male, Wistar | 215–475 g | 7 weeks | MRSA (clinical isolate IDRL 6169), 50 μl of 5 × 105 CFU/ml | Injection into intramedullary canal | Drill defect into tibial metaphysis with medullary cavity exposure. Placement of wire into canal. Sealed with dental gypsum | Microbiology |
| Hamza et al. ( | Intra-cellular | Male, Sprague-Dawley | 400–450 g | 3 weeks | Mid-shaft femoral fracture created | Blood analyses, radiographs, microbiology | ||
| Sanchez et al. ( | Effects of local delivery of D-amino acids from biofilm-dispersive scaffolds on infection in contaminated rat segmental defects | Sprague-Dawley | N/A | 2 weeks | 6 mm segmental femoral defect, stabilized with polyacetyl plate and K-wires | Microbiology | ||
| Søe et al. ( | A novel knee prosthesis model of implant-related osteomyelitis in rats | Male, Sprague-Dawley | 6–9 weeks, 300 g | 42 days | Injection into intramedullary canals | Non-constrained knee prosthesis | Radiographs, microbiology, histology, biochemical analysis | |
| Fölsch et al. ( | Coating with a novel gentamicinpalmitate formulation prevents implant-associated osteomyelitis induced by methicillin-susceptible | Male, Sprague-Dawley | 5 months | 42 days | Injection into intramedullary canal | Reaming of femoral intramedullary cavity | Blood analyses, radiographs, microbiology | |
| Stadelmann et al. ( | Female, Wistar | 15 weeks, 276 g | 28 days | Drill defect into tibial metaphysis. Placement of experimental implant | ||||
| Vergidis et al. ( | Comparative activities of vancomycin, tigecycline and rifampin in a rat model of methicillin-resistant | Male, Wistar | 250–350 g | 7 and 9 weeks | MRSA (clinical isolate IDRL-6169), 5 × 105 CFU/ml | Injection into intramedullary canal | Drill defect into tibial metaphysis with medullary cavity exposure. Placement of wire into canal. Sealed with dental gypsum | Microbiology |
| Avdeeva et al. ( | Experimental simulation of traumatic osteomyelitis in rats | Male, Albino | 200–250 g | 21 days |
| Injection into intramedullary canal | Defect to distal femoral metaphysis with thick needle | Blood analyses, histology |
| Fölsch et al. ( | Systemic antibiotic therapy does not significantly improve outcome in a rat model of implant-associated osteomyelitis induced by Methicillin susceptible | Male, Sprague-Dawley | 5 months | 42 days | Injection into intramedullary canal | Reaming of femoral intramedullary cavity | Blood analyses, radiographs, microbiology | |
| Harrasser et al. ( | A new model of implant-related osteomyelitis in the metaphysis of rat tibiae | Male, Wistar | 5 months, 350–400 g | 42 days | Injection into intramedullary canal | Unicortical tibial metaphyseal defect with placement of experimental implant | Radiographs, microbiology, histology | |
| Oh et al. ( | Antibiotic-eluting hydrophilized PMMA bone cement with prolonged bactericidal effect for the treatment of osteomyelitis | Sprague-Dawley | 250–300 g | 4 and 8 weeks | Injection into intramedullary canal | Defect to distal femur with medullary exposure. Sealed with bone wax | MicroCT, blood analysis | |
| Park et al. ( | Activity of tedizolid in methicillin-resistant | Male, Wistar | 250–350 g | 7 weeks | MRSA (clinical isolate IDRL-6169), 50 μl of 106 CFU/ml | Injection into intramedullary canal | Drill defect into tibial metaphysis with medullary cavity exposure. Placement of wire into canal. Sealed with dental gypsum | Microbiology |
| Hassani Besheli et al. ( | Sustainable release of vancomycin from silk fibroin nanoparticles for treating severe bone infection in rat tibia osteomyelitis model | Male, Wistar | 260–330 g | 3 weeks | MRSA, ATCC 43300, 40 μl of 1–2 × 108 CFU/ml | Injection into intramedullary canal | Burr defect into tibial metaphysis, placement of K-wire | Blood analysis, histology |
| Cui et al. ( | Masquelet induced membrane technique for treatment of rat chronic osteomyelitis | Male, Sprague-Dawley | 8 week, 190–220 g | 20 weeks | Injection into intramedullary canal | Modified blunt trauma method ( | Blood analyses | |
| Kussman et al. ( | Dalbavancin for treatment of implant-related methicillin- resistant | Male, Sprague-Dawley | 260–330 g | 3 weeks | MRSA ATCC 43300, 40 μl of 1–2 × 108 CFU/ml | Injection into intramedullary canal | Burr defect into tibial metaphysis, placement of K-wire | Blood analysis, histology |
| Melicherčík et al. ( | Testing the efficacy of antimicrobial peptides in the topical treatment of induced osteomyelitis in rats | Male, Wistar | 250 g | 17 days | Injection into intramedullary canal | Reaming of femoral intramedullary cavity | Radiographs | |
| Neyisci et al. ( | Treatment of implant-related methicillin- resistant | Female, Sprague-Dawley | 18–20 weeks | 4 weeks | MRSA N315 (NBCI Taxonomy ID: 158879), 108 CFU/ml | Injection into intramedullary canal | Reaming of tibial intramedullary canal with K-wire. Insertion of needle into canal. Sealed with bone wax. Implant removal at 2 weeks | Radiographs, microbiology, histology |
| Cobb et al. ( | CRISPR-Cas9 modified bacteriophage for treatment of | Female, Sprague-Dawley | 13 weeks | 8 days | Bicortical drill defect to mid-femoral diaphysis. Placement of contaminated screws | Radiographs with fluorescent overlays, microbiology, histology, SEM | ||
| Jung et al. ( | Sprague-Dawley | N/A | 3 and 6 weeks | Injection into intramedullary canal | Defect to distal femur with medullary exposure. Sealed with bone wax | MicroCT, microbiology | ||
| Wu et al. ( | Virulence of methicillin-resistant | Female, Sprague-Dawley | 260–280 g | 4 weeks | MRSA (clinical strain) and ASyycG over- expression MRSA clinical strain (ASyycG mutant). 40 μl of mid-exponential phase | Injection into intramedullary canal | Drill defect to antero-medial tibia with medullary cavity exposure | |
| Zhou et al. ( | The synergistic therapeutic efficacy of vancomycin and omega-3 fatty acids T alleviates | Male, Albino | 180–200 g | At least 7 days | MRSA 1 × 106 CFU/ml | Injection into intramedullary canal | Defect to tibial metaphysis, with medullary exposure, | Biochemical markers, histology, microbiology |
| Deng et al. ( | Extracellular Vesicles: A potential biomarker for quick identification of infectious osteomyelitis | Male, Wistar | 8–10 weeks, 300–350 g | At least 3 days | Injection into intramedullary canal | Defect to tibial metaphysis, with medullary exposure, | Serum extracellular vesicles | |
| Sahukhal et al. ( | The role of the msaABCR operon in implant-associated chronic osteomyelitis in | Sprague-Dawley | 250–300 g | 4, 8 and 15 days | K-wire pin insertion into tibial metaphysis | MicroCT, microbiology, histology, cytokine analysis | ||
| Qu et al. ( | Zinc alloy-based bone internal fixation screw with antibacterial and anti-osteolytic properties | Male, Sprague-Dawley | 3 months | 3 and 6 weeks | MRSA ATCC 43300, 107 CFU | Defect between distal femoral condyles with medullary exposure. Contaminated implant placed. Sealed with bone wax. | Radiographs, microbiology, histology, blood analyses, | |
| Sodnomi-Ish et al. ( | Decompression effects on bone healing in rat mandible osteomyelitis | Male, Sprague-Dawley | 8 week, 230 g | 4 weeks | Injection into defect | 4 mm defect to mandibular ramus, sealed with fibrin glue | MicroCT, histology, immunohisto |
Asterisks denote papers deemed by the authors to be seminal to rat osteomyelitis modeling.